Knuff & Co LLC Cuts Holdings in Moderna, Inc. (NASDAQ:MRNA)

Knuff & Co LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA) by 18.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,877 shares of the company’s stock after selling 855 shares during the period. Knuff & Co LLC’s holdings in Moderna were worth $161,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Wilmington Savings Fund Society FSB grew its stake in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna during the 4th quarter valued at about $37,000. Venturi Wealth Management LLC boosted its stake in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares during the period. Finally, Blue Trust Inc. lifted its position in Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after acquiring an additional 388 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

MRNA opened at $33.76 on Wednesday. The firm has a market cap of $13.03 billion, a P/E ratio of -3.64 and a beta of 1.86. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The company has a 50 day simple moving average of $36.38 and a two-hundred day simple moving average of $48.11.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Evercore ISI set a $50.00 target price on shares of Moderna in a report on Friday, February 14th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Morgan Stanley decreased their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $69.00 target price (down from $115.00) on shares of Moderna in a report on Monday, November 18th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.